Old Web
English
Sign In
Acemap
>
authorDetail
>
Ivy-Joan Madu
Ivy-Joan Madu
Medicine
Classic Congenital Adrenal Hyperplasia
dose escalation
Efficacy Study
Urology
3
Papers
2
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Tildacerfont for the Treatment of Patients With Classic Congenital Adrenal Hyperplasia: Results From a 12-Week Phase 2 Clinical Trial in Adults With Classic CAH
2021
Journal of the Endocrine Society
Richard J. Auchus
Deborah P. Merke
Ivy-Joan Madu
Samer Nakhle
Kyriakie Sarafoglou
Michael Huang
David Moriarty
Chris Barnes
Ron S. Newfield
Show All
Source
Cite
Save
Citations (0)
Tildacerfont in Adults with Classic Congenital Adrenal Hyperplasia: Results from Two Phase 2 Studies.
2021
The Journal of Clinical Endocrinology and Metabolism
Kyriakie Sarafoglou
Chris Barnes
Michael Huang
Erik A. Imel
Ivy-Joan Madu
Deborah P. Merke
David Moriarty
Samer Nakhle
Ron S. Newfield
Maria G. Vogiatzi
Richard J. Auchus
Show All
Source
Cite
Save
Citations (1)
SUN-LB064 A Phase 2, Dose-Escalation, Safety and Efficacy Study of Tildacerfont (SPR001) for the Treatment of Patients with Classic Congenital Adrenal Hyperplasia
2019
Journal of the Endocrine Society
Kyriakie Sarafoglou
Ron S. Newfield
Maria G. Vogiatzi
Erik A. Imel
A. Odugbesan
Ivy-Joan Madu
Samer Nakhle
Alexis Howerton
Huang Michael
Kelly Vandever
Rong Lin
Alyssa Wu-Zhang
Richard J. Auchus
Show All
Source
Cite
Save
Citations (1)
1